- Promotion of Jason Broome to role of chief research and innovation officer is expected to bolster strategic research program targeting global markets
- Flowr grows only premium cannabis using non-irradiated production methods that generate high crop yields at low operating costs
- Global cannabis market expected to reach $154.82 billion in sales by 2026
Several strategic advancements recently announced by The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF), a Canadian licensed producer of premium cannabis products, position the company to be a world leader in crafting high-quality cannabis that appeals to a growing worldwide consumer base for the legal cannabis recreational and medicinal markets.
Jason Broome, former senior vice president of operations, has been promoted to the role of chief research and innovation officer (“CRIO”) to lead the company’s innovative research and development efforts. Broome is tasked with developing new high-quality products and will focus on Flowr’s research into cultivars, form factors and delivery systems for the global markets. He will also oversee Flowr’s state-of-the-art R&D facility, which is part of a partnership with Hawthorne Canada, a subsidiary of The Scott’s Miracle-Gro Corporation (NYSE: SMG) (http://ibn.fm/CO9XJ).
“Flowr’s product innovation portfolio must meet the world-class standards of our cultivation,” Tom Flow, co-CEO of Flowr, said in a news release announcing Broome’s promotion (http://ibn.fm/7cFNd). “It’s an unusually demanding ask, but Jason’s expertise across all aspects of product development, from molecule to market, is unique and yet totally in keeping with Flowr’s high-performance, high-creativity culture.”
Flowr’s flagship facility, an approximately 85,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols that produce high crop yields at low operating costs, enables Flowr to grow cannabis that meets Health Canada’s stringent standards while striving to avoid treating it with the taste- and smell-killing gamma irradiation that most other LP’s use to clean their product.
Canada opened up recreational cannabis to adult users in October 2018 and has since released new regulations governing cannabis-infused edibles and beverages, along with cannabis concentrates, which are set to be legalized in mid-October 2019. According to Stratistics MRC, the global cannabis market accounted for $10.39 billion in 2017 sales and is expected to reach $154.82 billion by 2026, growing at a compound annual growth rate of 35 percent during the forecast period (http://ibn.fm/WacxT).
In a career spanning more than 15 years, Broome has led the commercialization of major pharmaceutical brands; built, operated and sold several health care-related companies; and brought disruptive technologies and systems to market. Within the cannabis sector, he was co-founder of the first company licensed to cultivate and extract hemp in Kentucky and served as chief operating officer of a Colorado manufacturer of cannabidiol (CBD) oil. He holds a master’s degree in molecular genetics from the University of Ottawa.
Broome will work closely with Dr. Lyle Oberg, chief policy and medical officer of Flowr, and Dr. Deron Caplan, North America’s first cannabis cultivation Ph.D., along with celebrated Canadian chef Ryan Reed, who has been tasked with developing signature edible cannabis products for the Flowr brand (http://ibn.fm/XSBrG).
For more information, visit the company’s website at www.Flowr.ca
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.